Relay Therapeutics Inc. (RLAY)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates
Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.45 per share a year ago.
Relay Therapeutics, Inc. (RLAY) Presents at Jefferies London Healthcare Conference 2025 Transcript
Relay Therapeutics, Inc. ( RLAY ) Jefferies London Healthcare Conference 2025 November 19, 2025 6:30 AM EST Company Participants Sanjiv Patel - CEO, President & Director Peter Rahmer - Chief Corporate Development Officer Conference Call Participants Zaki Molvi - Jefferies LLC, Research Division Presentation Zaki Molvi Jefferies LLC, Research Division All right. Good morning, everyone.
Wall Street Analysts Think Relay Therapeutics (RLAY) Could Surge 86.05%: Read This Before Placing a Bet
The consensus price target hints at an 86.1% upside potential for Relay Therapeutics (RLAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Relay Therapeutics Inc. (RLAY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Relay Therapeutics Inc. ever had a stock split?
Relay Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Sanjiv K. Patel CEO | NASDAQ (NMS) Exchange | 75943R102 CUSIP |
| US Country | 259 Employees | - Last Dividend | - Last Split | 16 Jul 2020 IPO Date |
Overview
Relay Therapeutics, Inc. is a cutting-edge clinical-stage precision medicines company deeply invested in changing the landscape of drug discovery. With a keen focus on developing small molecule therapeutics aimed at targeted oncology and genetic disease indications, the company is pioneering efforts to enhance the drug discovery process. Originating under the name Allostery, Inc., the organization rebranded to Relay Therapeutics, Inc. in December 2015, situating its headquarters in Cambridge, Massachusetts. Since its incorporation in 2015, Relay Therapeutics has forged vital collaborations and license agreements with leading entities such as D. E. Shaw Research, LLC, and Genentech, Inc., leveraging advanced computational modeling capabilities and focusing on the analyzation of protein motion to develop novel compounds targeting critical biological pathways.
Products and Services
- RLY-4008: This is an oral small molecule inhibitor targeting the fibroblast growth factor receptor 2 (FGFR2), currently undergoing a first-in-human clinical trial. It is specifically designed for patients with advanced or metastatic FGFR2-altered solid tumors, marking a significant stride forward in targeted oncology.
RLY-4008 represents a pioneering approach to cancer treatment, focusing on harnessing the potential of specifically inhibiting FGFR2 to combat various forms of cancer. The clinical trial aims to evaluate its efficacy and safety in a patient population with few other therapeutic options.
- RLY-2608: This candidate is a leading mutant-PI3Ka inhibitor program, aiming at the phosphoinositide 3-kinase alpha (PI3Ka), a crucial enzyme involved in the signaling pathways that control cell growth and survival.
The development of RLY-2608 centers around its potential to offer a targeted therapy option for patients with tumors driven by mutations in the PI3Ka pathway. Relay Therapeutics’ focus on this molecule underscores the company’s commitment to addressing cancer's genetic complexities.
- Migoprotafib (GDC-1971): As a potent and selective inhibitor of the protein tyrosine phosphatase SHP2, Migoprotafib showcases how small molecule therapeutics can be tailored to interact with critical oncogenic proteins. This oral small molecule acts by binding and stabilizing Src homology region 2 domain-containing phosphatase-2 (SHP2), with its applications being explored as a monotherapy in patients with advanced or metastatic solid tumors.
The collaboration with Genentech, Inc. for the development and commercialization of GDC-1971 (Migoprotafib) highlights its potential to be a breakthrough in cancer therapy, potentially offering new hope to patients with advanced cancers through targeted therapeutic strategies.
